Oxford BioMedica welcomes Stuart Paynter to its board
February 28, 2017Cell therapy and a gene group Oxford BioMedica has named Stuart Paynter new CFO to succeed Tim Watts, who has decided to retire from full time executive roles.
Paynter, who is currently Finance Director, Head of Business Partnering at De La Rue, will start in his role on August 29, 2017 at which point he will also join the Board, the company said.
Tim Watts joined Oxford BioMedica in early 2012 and will remain with the Group until 29 September 2017 in order to facilitate an orderly transition, the company said.
